Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults Dec. 05, 2024 6:45 AM ET ...

Virologic and Clinical Outcomes Among Participants Hospitalized in a Phase 3 Trial Comparing Molnupiravir with Placebo for Treating Mild-to-Moderate COVID-19. M. Johnson .

Merck Agrees to Allow Other Drug Makers to Produce Its Potentially Game-Changing COVID-19 Pill. The medicine has repeatedly made headlines for the "compelling results" seen in clinical trials.

The U.S. government has agreed to purchase 1.4 million more courses of molnupiravir, Merck's experimental COVID-19 antiviral drug, for roughly $1 billion, the drugmaker said Nov. 9.

Merck is asking the FDA for emergency approval of COVID-19 antiviral pill molnupiravir, after trials for the drug showed promising results.

KENILWORTH, N.J.& MIAMI---- Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the Japanese government will purchase, upon authorization ...

Drugmaker Merck announced on Friday that it would soon seek approval from the U.S. Food and Drug Administration for a pill the company claims cuts the risk of hospitalization or death from Covid ...

Merck said Monday it is seeking US Food and Drug Administration emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir. Posted 10:01 a.m. Oct 11, 2021 ...

The Medicines Patent Pool on Jan. 20 said it had signed agreements with 27 generic drugmakers to manufacture molnupiravir — Merck's COVID-19 antiviral — to advance accessibility in 105 ...

How Merck's antiviral pill could change the game for COVID-19. Promising results from clinical trials suggest that the drug may become the first at-home treatment cleared for use by the FDA.